- Lobe Sciences’ (LOBE) patent-pending therapeutic regimen designed for treating mTBI and PTSD has been published by the World Intellectual Property Organization
- Lobe’s partners at the University of Miami are continuing to run in vivo tests on the company’s combination therapies
- Lobe Sciences is a life sciences company focused on psychedelic medicines
- Lobe Sciences Ltd. (LOBE) opened trading at C$0.035 per share
Lobe Sciences’ (LOBE) patent-pending therapeutic regimen designed for treating mTBI and PTSD has been published by the World Intellectual Property Organization.
Philip Young, CEO & Director, commented on the news.
“The publication of our PCT patent application demonstrates our continued commitment to developing novel treatments for diseases where there is no approved treatment. Our partners at the University of Miami are continuing to run in vivo tests on these patent-pending combination therapies. I look forward to updating the investor community on our progress and plans for 2022.”
Lobe Sciences is a life sciences company focused on psychedelic medicines. The company is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
Lobe Sciences Ltd. (LOBE) opened trading at C$0.035 per share.